Table 1.
Characteristics of included studies
| Author, Year | Location | Study Period | Sample Size | Diagnostic Method (scoring system) | Duration of follow-up (mean; total person-years) | Reported data for NAFLD-related condition (Y, N) | ||
|---|---|---|---|---|---|---|---|---|
| Simple Steatosis | NASH | Fibrosis | ||||||
| A. Randomized Controlled Trials | ||||||||
| Armstrong, 201654 | UK | 2010–2014 | 22 | Biopsy (Brunt) | 0.9; 20.3 | N | Y | Y |
| Bril, 201955 | USA | 2010–2016 | 32 | Biopsy (Brunt) | 1.5; 48 | N | Y | N |
| Chan, 201756 | Malaysia | 2012–2015 | 50 | Biopsy (NASH CRN) | 0.9; 46.2 | N | Y | Y |
| Friedman, 201819 | Multinational | 2014–2016 | 126 | Biopsy (NASH CRN) | 1; 126 | N | Y | Y |
| Harrison, 201829 | Multinational | 2012–2016 | 159 | Biopsy (NASH CRN) | 1.8; 293.5 | N | Y | Y |
| Harrison, 201920 | USA | 2016–2019 | 74 | Biopsy (NASH CRN) | 1; 74 | N | Y | N |
| Harrison, 202017 | Multinational | 2016–2019 | 105 | Biopsy (NASH CRN) | 1.4; 145.4 | N | Y | Y |
| Harrison, 202030 | Multinational | 2017–2019 | 331 | Biopsy (NASH CRN) & FibroScan | 0.9; 305.5 | N | Y | Y |
| Loguercio, 201231 | Italy | 2005–2008 | 53 | Biopsy (Brunt) | 1; 53 | N | N | Y |
| Neuschwander-Tetri, 201532 | USA | 2011–2014 | 142 | Biopsy (NASH CRN) | 1.4; 196.6 | Y | Y | Y |
| Newsome, 202057 | UK | 2016–2020 | 80 | Biopsy (Brunt) | 1.4; 110.4 | N | Y | Y |
| Ratziu, 201622 | Multinational | 2012–2015 | 92 | Biopsy (NASH CRN) | 1; 92 | N | Y | N |
| Ratziu, 202023 | Multinational | 2014–2017 | 72 | Biopsy (NASH CRN) | 2; 144 | N | N | Y |
| Sanyal, 201025 | USA | 2005–2009 | 83 | Biopsy (NASH CRN) | 1.8; 132.9 | N | Y | N |
| VanWagner, 201158 | USA | 2005–2009 | 9 | Biopsy (Brunt) | 1; 9 | N | Y | N |
| Wong, 201327 | HK, China | 2009–2012 | 77 | H-MRS | 1; 77 | Y | N | N |
| Younossi, 201928 | Multinational | 2015–2018 | 311 | Biopsy (NASH CRN) | 1.5; 466.5 | N | Y | N |
| Zein, 201159 | USA | 2006–2010 | 26 | Biopsy (Brunt) | 1; 26 | N | Y | N |
| B. Observational Studies | ||||||||
| Ajmera, 201818 | USA | 2009–2017 | 95 | Biopsy (NASH CRN) | 1.7; 161.5 | N | Y | N |
| Akuta, 201652 | Japan | 1980–2016 | 36 | Biopsy (Brunt) | 4.6; 165.6 | N | N | Y |
| Castro, 201933 | Brazil | 2005–2011 | 39 | Biopsy (NASH CRN) & Fibroscan | 10; 390 | N | N | Y |
| Chan, 201460 | Malaysia | 2003–2010 | 35 | Biopsy (NASH CRN) | 6.4; 224 | N | Y | Y |
| Cho, 201961 | Korea | 2000–2010 | 2726 | Ultrasound | 5.2; 14129.8 | Y | N | N |
| Ekstedt, 20065 | Sweden | 1988–2005 | 68 | Biopsy (Brunt) | 13.7; 938.4 | N | N | Y |
| Evans, 200234 | UK | 1985–1999 | 46 | Biopsy (Brunt) | 8.2; 377.2 | N | N | Y |
| Fassio, 200435 | Argentina | 1986–2002 | 22 | Biopsy (Brunt) | 4.3; 94.6 | N | N | Y |
| Hamaguchi, 201062 | Japan | 1997–2008 | 39 | Biopsy (Brunt) | 2.4; 93.6 | Y | Y | Y |
| Harrison, 200321 | USA | 1985–2001 | 22 | Biopsy (Brunt) | 5.7; 125.4 | N | N | Y |
| Hui, 200536 | HK, China | 1996–2004 | 17 | Biopsy (Brunt) | 5.8; 97.8 | N | N | Y |
| Kamarajah, 201844 | Malaysia | 2012–2017 | 113 | Biopsy (NASH CRN) & Fibroscan | 3.1; 348.4 | N | N | Y |
| Kim, 200937 | South Korea | 2000–2005 | 2895 | Ultrasound | 5; 14475 | Y | N | N |
| Kim, 201842 | South Korea | 2007–2013 | 956 | Ultrasound | 4.6; 4397.6 | Y | N | N |
| Kleiner, 201946 | USA | 2004–2013 | 446 | Biopsy (NASH CRN) | 4.9; 2185.4 | Y | Y | Y |
| Lee, 201043 | South Korea | 2004–2007 | 1705 | Ultrasound | 2.2; 3716 | Y | N | N |
| Lin, 201938 | Taiwan | 2001–2010 | 10 | Biopsy (NASH CRN) | 2.4; 23.9 | N | N | Y |
| McPherson, 201563 | UK | 1991–2011 | 108 | Biopsy (NASH CRN) | 6.6; 712.8 | N | Y | Y |
| Moreno Sanchez, 199112 | Spain | 1980–1985 | 10 | Biopsy (METAVIR) | 4.8; 48.3 | N | N | Y |
| Nasr, 201839 | Sweden | 1988–2015 | 32 | Biopsy (NASH CRN) | 9.1; 291.3 | N | N | Y |
| Nogami, 201964 | Japan | 2006–2017 | 34 | Biopsy (NASH CRN) | 10; 340 | N | N | Y |
| Pais, 201140 | France | 1998–2009 | 6 | Biopsy (Kleiner) | 4.8; 28.8 | N | Y | Y |
| Pais, 201365 | France | 1998–2009 | 70 | Biopsy (Brunt) | 3.4; 238 | N | Y | Y |
| Reddy, 202024 | USA | 2006–2016 | 36 | Biopsy (NASH CRN) | 3.8; 136.8 | N | Y | N |
| Seko, 201566 | Japan | 1999–2014 | 52 | Biopsy (NASH CRN) | 2.7; 137.8 | N | Y | Y |
| Seo, 201567 | South Korea | 2006–2009 | 1916 | Ultrasound | 4.2; 8047.2 | Y | N | N |
| Shen, 201226 | HK, China | 2004–2010 | 51 | Biopsy (NASH CRN) | 3; 153 | N | Y | N |
| Teli, 199541 | UK | 1978–1994 | 40 | Biopsy (defined in study) | 8.6; 345.7 | Y | Y | Y |
| Vilar-Gomez, 202068 | USA | 2004–2016 | 90 | Biopsy (NASH CRN) | 5.6; 504 | N | Y | N |
| Wang, 201869 | China | 2006–2014 | 6310 | Ultrasound | 7; 44170 | N | N | N |
| Wang, 202070 | China | 2010–2015 | 4273 | Ultrasound | 4.4; 18801.2 | Y | N | N |
| Wong, 201071 | HK, China | 2006–2009 | 52 | Biopsy (Brunt) | 3; 156 | N | Y | Y |
| Wong, 201516 | HK, China | 2008–2013 | 565 | H-MRS & FibroScan | 3.9; 2212.9 | Y | N | N |
| Zelber-Sagi, 201472 | Israel | 2003–2011 | 147 | Ultrasound | 6.8; 999.6 | Y | N | N |
| Zhang, 201973 | China | 2011–2014 | 1325 | Ultrasound | 3; 3975 | Y | N | N |
| Zhou, 201274 | China | 2005–2009 | 507 | Ultrasound | 4; 2028 | Y | N | N |
Note: HK, Hong Kong; H-MRS, Proton Magnetic Resonance Spectroscopy; NAFLD, Non-alcoholic Fatty Liver Disease; NASH, Non-alcoholic Steatohepatitis; NASH CRN, Non-alcoholic Steatohepatitis Clinical Research Network; N, no; Y, yes